Mammoth Biosciences partners with GSK to develop handheld CRISPR-based COVID-19 test

Mammoth Biosciences partners with GSK to develop handheld CRISPR-based COVID-19 test

4 years ago
Anonymous $-9GJQVHNr8

https://techcrunch.com/2020/05/20/mammoth-biosciences-partners-with-gsk-to-develop-handheld-crispr-based-covid-19-test/

California-based Mammoth Biosciences has signed a powerful partner for its development of a CRISPR-based test for COVID-19, which would aim to delivery accurate, fast results using a handheld, disposable testing platform. Mammoth Biosciences will be using its DETECTR platform to develop the test, which recently received validation through a peer-reviewed study published in Nature.

Already, Mammoth has its DETECTR platform under evaluation by the FDA for an Emergency Use Authorization (EUA), and partnering with GSK and its consumer healthcare division sets up Mammoth to potentially scale its development and distribution to widespread commercial and consumer availability. Mammoth and GSK aim to have a COVID-19-specific test based on DETECTR ready for FDA evaluation before the end of this year.

Mammoth Biosciences partners with GSK to develop handheld CRISPR-based COVID-19 test

May 20, 2020, 4:26pm UTC
https://techcrunch.com/2020/05/20/mammoth-biosciences-partners-with-gsk-to-develop-handheld-crispr-based-covid-19-test/ > California-based Mammoth Biosciences has signed a powerful partner for its development of a CRISPR-based test for COVID-19, which would aim to delivery accurate, fast results using a handheld, disposable testing platform. Mammoth Biosciences will be using its DETECTR platform to develop the test, which recently received validation through a peer-reviewed study published in Nature. > Already, Mammoth has its DETECTR platform under evaluation by the FDA for an Emergency Use Authorization (EUA), and partnering with GSK and its consumer healthcare division sets up Mammoth to potentially scale its development and distribution to widespread commercial and consumer availability. Mammoth and GSK aim to have a COVID-19-specific test based on DETECTR ready for FDA evaluation before the end of this year.